Breaking News

AGC Biologics, Molecular Partners to Develop DARPin Anti-COVID-19 Program

AGC Biologics will manufacture MP0420 at 100 liter and 1,000 liter scales for development and initial global supply.

By: Contract Pharma

Contract Pharma Staff

AGC Biologics is partnering with Molecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin. The companies will work together to develop their multi-specific DARPin anti-COVID-19 program, MP0420. Molecular Partners plans to initiate clinical studies for this program in 2H20. AGC Biologics will manufacture at 100 liter and 1,000 liter scales, which is suitable for development and initial global supply for patients in need. Based upon preliminary data, a ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters